INT85943

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1999
Last Reported 2011
Negated 2
Speculated 4
Reported most in Body
Documents 161
Total Number 169
Disease Relevance 108.56
Pain Relevance 42.65

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Nos2) signal transduction (Nos2) extracellular space (Nos2)
oxidoreductase activity (Nos2) peroxisome (Nos2) nucleus (Nos2)
Anatomy Link Frequency
macrophages 5
liver 5
sciatic nerve 4
peritoneal macrophages 3
neuronal 3
Nos2 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 1507 100.00 Very High Very High Very High
cytokine 788 100.00 Very High Very High Very High
Inflammatory mediators 103 100.00 Very High Very High Very High
COX2 71 100.00 Very High Very High Very High
Thermal hyperalgesia 135 99.82 Very High Very High Very High
Morphine 76 99.80 Very High Very High Very High
lidocaine 20 99.72 Very High Very High Very High
Analgesic 29 99.58 Very High Very High Very High
alcohol 11 99.52 Very High Very High Very High
intrathecal 47 99.40 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 1797 100.00 Very High Very High Very High
Targeted Disruption 1483 100.00 Very High Very High Very High
Obesity 1379 100.00 Very High Very High Very High
Aberrant Crypt Foci 14 100.00 Very High Very High Very High
Injury 395 99.86 Very High Very High Very High
Hyperalgesia 187 99.82 Very High Very High Very High
Hypothermia 87 99.80 Very High Very High Very High
Shock 95 99.70 Very High Very High Very High
Disease 631 99.62 Very High Very High Very High
Disease Susceptibility 3 99.56 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Interestingly, targeted disruption of iNOS gene did not affect carrageenan-induced thermal hyperalgesia in either the early (2-6 h) or late phase.
Negative_regulation (disruption) of iNOS associated with targeted disruption and thermal hyperalgesia
1) Confidence 0.59 Published 2003 Journal Neuroscience Section Abstract Doc Link 12895524 Disease Relevance 0.81 Pain Relevance 0.65
This effect was due to down-regulation of iNOS mRNA and suppression of iNOS proteins, i.e., blueberry extract may inhibit one of the primary steps in the inflammatory stress pathway [41].
Negative_regulation (suppression) of iNOS associated with stress and inflammation
2) Confidence 0.57 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2693933 Disease Relevance 0.86 Pain Relevance 0.20
We therefore concluded that lidocaine significantly inhibits iNOS and CAT-2 and, in turn, enhances GTPCH transcription in LPS-stimulated macrophages via a mechanism that possibly involves the voltage-sensitive Na+ channel.
Negative_regulation (inhibits) of iNOS in macrophages associated with lidocaine
3) Confidence 0.56 Published 2006 Journal Anesth. Analg. Section Abstract Doc Link 16717319 Disease Relevance 0 Pain Relevance 1.06
The structurally unrelated ER stressor, thapsigargin, also reduced iNOS activity, protein levels, and mRNA transcripts (data not shown).
Negative_regulation (reduced) of iNOS
4) Confidence 0.55 Published 2008 Journal Current Chemical Genomics Section Body Doc Link PMC2803434 Disease Relevance 0.14 Pain Relevance 0
These data indicate that compound 1 acts upstream in the iNOS pathway and reduces NO production in cells by reducing iNOS protein levels.
Negative_regulation (reducing) of iNOS protein
5) Confidence 0.55 Published 2008 Journal Current Chemical Genomics Section Body Doc Link PMC2803434 Disease Relevance 0 Pain Relevance 0
The concentrations of erstressin required to activate UPR signaling and UPR gene expression are the same as those that reduce iNOS mRNA and protein expression and enzyme activity.
Negative_regulation (reduce) of iNOS
6) Confidence 0.55 Published 2008 Journal Current Chemical Genomics Section Body Doc Link PMC2803434 Disease Relevance 0.12 Pain Relevance 0
Lidocaine at 500 mg/mL decreased iNOS protein levels.
Negative_regulation (decreased) of iNOS protein associated with lidocaine
7) Confidence 0.51 Published 2001 Journal Anesth. Analg. Section Abstract Doc Link 11133614 Disease Relevance 0.36 Pain Relevance 0.80
Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase.
Negative_regulation (inhibition) of inducible nitric oxide synthase associated with fortral and agonist
8) Confidence 0.51 Published 2006 Journal Anesth. Analg. Section Title Doc Link 16861428 Disease Relevance 0.39 Pain Relevance 0.34
An examination of lung metastases, which are significantly reduced in PyMT/iNOS?
Negative_regulation (reduced) of iNOS in lung associated with metastasis
9) Confidence 0.51 Published 2007 Journal Transgenic Res Section Abstract Doc Link PMC1829418 Disease Relevance 1.19 Pain Relevance 0
We have shown that in the PyMT B6 background loss of iNOS, an important inflammatory mediator, results in increased tumor latency and decreased tumor metastasis that is not due simply to the difference in latency.
Negative_regulation (loss) of iNOS associated with inflammation, cancer and metastasis
10) Confidence 0.51 Published 2007 Journal Transgenic Res Section Body Doc Link PMC1829418 Disease Relevance 1.00 Pain Relevance 0.22
C. racemosa extracts did not significantly inhibit iNOS activity and did not affect nuclear translocation of nuclear factor-kappaB (p65 subunit) protein.
Negative_regulation (inhibit) of iNOS
11) Confidence 0.51 Published 2009 Journal J. Pharm. Pharmacol. Section Body Doc Link 19703353 Disease Relevance 0 Pain Relevance 0
These results provide evidence that blockade of NO overproduction, the consequence of NMDA receptor activation, by aminoguanidine, via inhibition of iNOS, can attenuate the development of morphine tolerance and dependence.
Negative_regulation (inhibition) of iNOS associated with addiction, nmda receptor, tolerance and morphine
12) Confidence 0.51 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16730698 Disease Relevance 0 Pain Relevance 0.98
The anti-inflammatory mechanisms of ST1 might be related to the decrease in the level of MDA, iNOS, and COX-2 in the edema paw via increasing the activities of CAT, SOD, and GPx in the liver through the suppression of TNF-alpha and NO.
Negative_regulation (decrease) of iNOS in liver associated with pressure and volume under development and inflammation
13) Confidence 0.50 Published 2010 Journal J. Agric. Food Chem. Section Abstract Doc Link 20507140 Disease Relevance 0.96 Pain Relevance 0.30
The antinociceptive interaction of rofecoxib, a selective cyclooxygenase-2 inhibitor, with aminoguanidine hydrochloride, a selective iNOS inhibitor, was examined in the formalin-induced paw-licking model in mice.
Negative_regulation (inhibitor) of iNOS in paw associated with antinociceptive
14) Confidence 0.50 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15178354 Disease Relevance 0.07 Pain Relevance 0.17
The data show that the inhibitory activities of alpha- and gamma-mangostins are not due to direct inhibition of iNOS enzyme activity.
Negative_regulation (inhibition) of iNOS
15) Confidence 0.49 Published 2008 Journal Food Chem. Toxicol. Section Abstract Doc Link 18029076 Disease Relevance 0.22 Pain Relevance 0.11
We have identified a novel small molecule activator of the unfolded protein response (UPR) pathway in a chemical genetic screen for inhibitors of iNOS.
Negative_regulation (inhibitors) of iNOS
16) Confidence 0.48 Published 2008 Journal Current Chemical Genomics Section Body Doc Link PMC2803434 Disease Relevance 0.57 Pain Relevance 0.21
This approach enables not only the detection of compounds that inhibit iNOS directly, but also compounds that act upstream in the iNOS-NO axis.
Negative_regulation (inhibit) of iNOS
17) Confidence 0.48 Published 2008 Journal Current Chemical Genomics Section Body Doc Link PMC2803434 Disease Relevance 0.09 Pain Relevance 0.05
Additional mechanisms, such as selective or non-selective translational attenuation, may further contribute to the overall reduction in iNOS protein.
Negative_regulation (reduction) of iNOS protein
18) Confidence 0.48 Published 2008 Journal Current Chemical Genomics Section Body Doc Link PMC2803434 Disease Relevance 0.45 Pain Relevance 0.13
As seen in Fig. (2C), a statistically significant reduction in iNOS transcripts was measured following treatment with compound 1 relative to either compound 2 or vehicle (DMSO).
Negative_regulation (reduction) of iNOS
19) Confidence 0.48 Published 2008 Journal Current Chemical Genomics Section Body Doc Link PMC2803434 Disease Relevance 0 Pain Relevance 0.03
The levels of myeloperoxidase and iNOS activities were also significantly decreased in DA-9601-treated group compared to the pancreatitis only group.
Negative_regulation (decreased) of iNOS
20) Confidence 0.47 Published 2005 Journal Pancreatology Section Body Doc Link 15849487 Disease Relevance 0.19 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox